Oragenics Files 8-K: Material Agreements, Officer Changes, Shareholder Votes
Ticker: OGEN · Form: 8-K · Filed: May 2, 2025 · CIK: 1174940
Sentiment: neutral
Topics: material-agreement, corporate-governance, officer-changes, shareholder-vote
TL;DR
Oragenics dropped an 8-K: new deals, exec shakeups, and shareholder votes are on the table.
AI Summary
On May 2, 2025, Oragenics, Inc. filed an 8-K report detailing several key events. These include the entry into a material definitive agreement, changes in directors and officers, and matters submitted to a vote of security holders. The filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing provides crucial updates on Oragenics' corporate governance and strategic agreements, which could impact its future operations and stock performance.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate actions including material agreements and changes in leadership, which inherently carry a medium level of risk and uncertainty.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- May 2, 2025 (date) — Date of Report
FAQ
What type of material definitive agreement did Oragenics enter into?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this summary.
Were there any changes in Oragenics' directors or officers?
Yes, the filing reports on the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
Were any matters submitted to a vote of Oragenics' security holders?
Yes, the filing states that matters were submitted to a vote of security holders.
What is the principal executive office address for Oragenics?
The address of the principal executive office is 1990 Main Street, Suite 750, Sarasota, FL 34236.
What is Oragenics' fiscal year end?
Oragenics' fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 2, 2025 regarding ORAGENICS INC (OGEN).